PACIFIC BIOSCIENCES OF CALIF
PACBNASDAQ🏆 #2940 by market capEarnings Nov 3US Equity
$1.83▲ $0.13 (+7.02%)
🌙 After hours$1.82▼ 0.55%Regular close · extended-hours price shownTrack PACB
Get earnings, price moves & breaking news on Telegram
24h▲ 7.0%
7d▲ 23.6%
14d▲ 36.6%
30d▲ 31.2%
ytd▼ 2.7%
1y▲ 45.8%
🏦Market Cap
$568M
Small Cap
📈Revenue Growth (YoY)
+2.0%
Slowing
📊Gross Margin
39.2%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
3.2x
Fair
Otter Score
64
Fair
PACIFIC BIOSCIENCES OF CALIF
PACBAnalyst Ratings
Price
$1.83
Total
18
Raised
2
Lowered
4
Avg PT
$1.18
H / L
$1 / $1
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Barclays | Reiterated | Underweight | 2026-05-11 | $1.00 | −45.40% |
Piper Sandler | Reiterated | Neutral | 2025-11-11 | $2.00 | +9.30% |
Stephens & Co. | Reiterated | Overweight | 2025-11-10 | — | — |
Canaccord Genuity | Reiterated | Buy | 2025-04-10 | $3.50 | +91.30% |
Scotiabank | Reiterated | Sector Outperform | 2025-03-25 | — | — |
Goldman Sachs | Reiterated | Neutral | 2025-02-18 | $2.50 | +36.60% |
UBS | Downgraded | Buy → Neutral | 2024-11-11 | $1.35 | −26.20% |
Morgan Stanley | Reiterated | Equal Weight | 2024-08-12 | $4.00 | +118.60% |
Cantor Fitzgerald | Reiterated | Overweight | 2024-08-08 | — | — |
JP Morgan | Downgraded | Overweight → Neutral | 2024-04-22 | — | — |
Bernstein | Reiterated | Outperform | 2024-04-18 | $1.70 | −7.10% |
TD Cowen | Reiterated | Buy | 2024-04-17 | — | — |
Piper Jaffray | Upgraded | Neutral → Overweight | 2019-10-15 | — | — |
Cowen & Co. | Downgraded | Outperform → Market Perform | 2019-01-04 | — | — |
MKM Partners | Reiterated | Neutral | 2016-04-15 | — | — |
First Analysis | Reiterated | Overweight | 2016-04-15 | — | — |
PiperJaffray | Downgraded | Overweight → Neutral | 2016-02-04 | — | — |
William Blair | Upgraded | Market Perform → Outperform | 2015-05-01 | — | — |
Institution
Barclays
Reiterated · Underweight · 2026-05-11
$1.00
−45.40%
Piper Sandler
Reiterated · Neutral · 2025-11-11
$2.00
+9.30%
Stephens & Co.
Reiterated · Overweight · 2025-11-10
—
—
Canaccord Genuity
Reiterated · Buy · 2025-04-10
$3.50
+91.30%
Scotiabank
Reiterated · Sector Outperform · 2025-03-25
—
—
Goldman Sachs
Reiterated · Neutral · 2025-02-18
$2.50
+36.60%
UBS
Downgraded · Buy → Neutral · 2024-11-11
$1.35
−26.20%
Morgan Stanley
Reiterated · Equal Weight · 2024-08-12
$4.00
+118.60%
Cantor Fitzgerald
Reiterated · Overweight · 2024-08-08
—
—
JP Morgan
Downgraded · Overweight → Neutral · 2024-04-22
—
—
Bernstein
Reiterated · Outperform · 2024-04-18
$1.70
−7.10%
TD Cowen
Reiterated · Buy · 2024-04-17
—
—
Piper Jaffray
Upgraded · Neutral → Overweight · 2019-10-15
—
—
Cowen & Co.
Downgraded · Outperform → Market Perform · 2019-01-04
—
—
MKM Partners
Reiterated · Neutral · 2016-04-15
—
—
First Analysis
Reiterated · Overweight · 2016-04-15
—
—
PiperJaffray
Downgraded · Overweight → Neutral · 2016-02-04
—
—
William Blair
Upgraded · Market Perform → Outperform · 2015-05-01
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space